

18 July 2018

ASX ANNOUNCEMENT

CEO Long Term Incentive Plan

The Board of Directors is pleased to announce it has agreed to a Long Term Incentive Plan “LTIP” with Mr. John Sharman, the CEO of Medical Developments International Limited (ASX: MVP) to encourage his long term commitment to the business.

Under the plan Mr. Sharman has been granted 300,000 options with a strike price of \$0.01.

When the LTIP has met its vesting criteria, Mr. Sharman will have 3 months to exercise the options, after which the options will lapse. 60% of any new shares issued by exercising options will be escrowed for a period of 12 months from issue date. In the case of an unconditional takeover, the escrow conditions will not apply.

All outstanding options will be cancelled if Mr. Sharman leaves or he is no longer employed by MVP for any reason.

This announcement is a high-level summary of the LTIP, details of which will be included in the FY18 Annual Report.

Enquiries:

David Williams
Chairman
Medical Developments International Ltd
0414 383 593

**About Medical Developments International Ltd**

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Pentrox®, a fast acting trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.